Analysis of factor V in zebrafish demonstrates minimal levels needed for early hemostasis

Angela C. Weyand, Steve J. Grzegorski, Megan S. Rost, Kari I. Lavik, Allison C. Ferguson, Marzia Menegatti, Catherine E. Richter, Rosanna Asselta, Stefano Duga, Flora Peyvandi, Jordan A. Shavit

Research output: Contribution to journalArticle

Abstract

In humans, coagulation factor V (FV) deficiency is a rare, clinically heterogeneous bleeding disorder, suggesting that genetic modifiers may contribute to disease expressivity. Zebrafish possess many distinct advantages including high fecundity, optical clarity, external development, and homology with the mammalian hemostatic system, features that make it ideal for genetic studies. Our aim was to study the role of FV in zebrafish through targeted mutagenesis and apply the model to the study of human F5 variants. CRISPR-mediated genome editing of the zebrafish f5 locus was performed, generating mutants homozygous for a 49 base pair deletion in exon 4. Thrombus formation secondary to vascular endothelial injury was absent in f52/2 mutant embryos and larvae. Despite this severe hemostatic defect, homozygous mutants survived before succumbing to severe hemorrhage in adulthood. Human F5 variants of uncertain significance from patients with FV deficiency were evaluated, and the causative mutations identified and stratified by their ability to restore thrombus formation in larvae. Analysis of these novel mutations demonstrates variable residual FV function, with minimal activity being required to restore hemostasis in response to laser-induced endothelial injury. This in vivo evaluation may be beneficial for patients whose factor activity levels lack correlation with bleeding symptomatology, although limitations exist. Furthermore, homozygous mutant embryos tolerate what is a severe and lethal defect in mammals, suggesting the possibility of species-specific factors enabling survival, and allowing further study not possible in the mouse. Identification of these factors or other genetic modifiers could lead to novel therapeutic modalities.

Original languageEnglish
Pages (from-to)1670-1680
Number of pages11
JournalBlood advances
Volume3
Issue number11
DOIs
Publication statusPublished - Jun 11 2019

Fingerprint

Factor V
Zebrafish
Factor V Deficiency
Hemostasis
Hemostatics
Hemorrhage
Larva
Thrombosis
Embryonic Structures
Clustered Regularly Interspaced Short Palindromic Repeats
Mutation
Inborn Genetic Diseases
Vascular System Injuries
Mutagenesis
Base Pairing
Causality
Fertility
Mammals
Exons
Lasers

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Weyand, A. C., Grzegorski, S. J., Rost, M. S., Lavik, K. I., Ferguson, A. C., Menegatti, M., ... Shavit, J. A. (2019). Analysis of factor V in zebrafish demonstrates minimal levels needed for early hemostasis. Blood advances, 3(11), 1670-1680. https://doi.org/10.1182/bloodadvances.2018029066

Analysis of factor V in zebrafish demonstrates minimal levels needed for early hemostasis. / Weyand, Angela C.; Grzegorski, Steve J.; Rost, Megan S.; Lavik, Kari I.; Ferguson, Allison C.; Menegatti, Marzia; Richter, Catherine E.; Asselta, Rosanna; Duga, Stefano; Peyvandi, Flora; Shavit, Jordan A.

In: Blood advances, Vol. 3, No. 11, 11.06.2019, p. 1670-1680.

Research output: Contribution to journalArticle

Weyand, Angela C. ; Grzegorski, Steve J. ; Rost, Megan S. ; Lavik, Kari I. ; Ferguson, Allison C. ; Menegatti, Marzia ; Richter, Catherine E. ; Asselta, Rosanna ; Duga, Stefano ; Peyvandi, Flora ; Shavit, Jordan A. / Analysis of factor V in zebrafish demonstrates minimal levels needed for early hemostasis. In: Blood advances. 2019 ; Vol. 3, No. 11. pp. 1670-1680.
@article{99a7c91401a34c75a8a8d7c3d2e1e415,
title = "Analysis of factor V in zebrafish demonstrates minimal levels needed for early hemostasis",
abstract = "In humans, coagulation factor V (FV) deficiency is a rare, clinically heterogeneous bleeding disorder, suggesting that genetic modifiers may contribute to disease expressivity. Zebrafish possess many distinct advantages including high fecundity, optical clarity, external development, and homology with the mammalian hemostatic system, features that make it ideal for genetic studies. Our aim was to study the role of FV in zebrafish through targeted mutagenesis and apply the model to the study of human F5 variants. CRISPR-mediated genome editing of the zebrafish f5 locus was performed, generating mutants homozygous for a 49 base pair deletion in exon 4. Thrombus formation secondary to vascular endothelial injury was absent in f52/2 mutant embryos and larvae. Despite this severe hemostatic defect, homozygous mutants survived before succumbing to severe hemorrhage in adulthood. Human F5 variants of uncertain significance from patients with FV deficiency were evaluated, and the causative mutations identified and stratified by their ability to restore thrombus formation in larvae. Analysis of these novel mutations demonstrates variable residual FV function, with minimal activity being required to restore hemostasis in response to laser-induced endothelial injury. This in vivo evaluation may be beneficial for patients whose factor activity levels lack correlation with bleeding symptomatology, although limitations exist. Furthermore, homozygous mutant embryos tolerate what is a severe and lethal defect in mammals, suggesting the possibility of species-specific factors enabling survival, and allowing further study not possible in the mouse. Identification of these factors or other genetic modifiers could lead to novel therapeutic modalities.",
author = "Weyand, {Angela C.} and Grzegorski, {Steve J.} and Rost, {Megan S.} and Lavik, {Kari I.} and Ferguson, {Allison C.} and Marzia Menegatti and Richter, {Catherine E.} and Rosanna Asselta and Stefano Duga and Flora Peyvandi and Shavit, {Jordan A.}",
year = "2019",
month = "6",
day = "11",
doi = "10.1182/bloodadvances.2018029066",
language = "English",
volume = "3",
pages = "1670--1680",
journal = "Blood advances",
issn = "2473-9529",
publisher = "American Society of Hematology",
number = "11",

}

TY - JOUR

T1 - Analysis of factor V in zebrafish demonstrates minimal levels needed for early hemostasis

AU - Weyand, Angela C.

AU - Grzegorski, Steve J.

AU - Rost, Megan S.

AU - Lavik, Kari I.

AU - Ferguson, Allison C.

AU - Menegatti, Marzia

AU - Richter, Catherine E.

AU - Asselta, Rosanna

AU - Duga, Stefano

AU - Peyvandi, Flora

AU - Shavit, Jordan A.

PY - 2019/6/11

Y1 - 2019/6/11

N2 - In humans, coagulation factor V (FV) deficiency is a rare, clinically heterogeneous bleeding disorder, suggesting that genetic modifiers may contribute to disease expressivity. Zebrafish possess many distinct advantages including high fecundity, optical clarity, external development, and homology with the mammalian hemostatic system, features that make it ideal for genetic studies. Our aim was to study the role of FV in zebrafish through targeted mutagenesis and apply the model to the study of human F5 variants. CRISPR-mediated genome editing of the zebrafish f5 locus was performed, generating mutants homozygous for a 49 base pair deletion in exon 4. Thrombus formation secondary to vascular endothelial injury was absent in f52/2 mutant embryos and larvae. Despite this severe hemostatic defect, homozygous mutants survived before succumbing to severe hemorrhage in adulthood. Human F5 variants of uncertain significance from patients with FV deficiency were evaluated, and the causative mutations identified and stratified by their ability to restore thrombus formation in larvae. Analysis of these novel mutations demonstrates variable residual FV function, with minimal activity being required to restore hemostasis in response to laser-induced endothelial injury. This in vivo evaluation may be beneficial for patients whose factor activity levels lack correlation with bleeding symptomatology, although limitations exist. Furthermore, homozygous mutant embryos tolerate what is a severe and lethal defect in mammals, suggesting the possibility of species-specific factors enabling survival, and allowing further study not possible in the mouse. Identification of these factors or other genetic modifiers could lead to novel therapeutic modalities.

AB - In humans, coagulation factor V (FV) deficiency is a rare, clinically heterogeneous bleeding disorder, suggesting that genetic modifiers may contribute to disease expressivity. Zebrafish possess many distinct advantages including high fecundity, optical clarity, external development, and homology with the mammalian hemostatic system, features that make it ideal for genetic studies. Our aim was to study the role of FV in zebrafish through targeted mutagenesis and apply the model to the study of human F5 variants. CRISPR-mediated genome editing of the zebrafish f5 locus was performed, generating mutants homozygous for a 49 base pair deletion in exon 4. Thrombus formation secondary to vascular endothelial injury was absent in f52/2 mutant embryos and larvae. Despite this severe hemostatic defect, homozygous mutants survived before succumbing to severe hemorrhage in adulthood. Human F5 variants of uncertain significance from patients with FV deficiency were evaluated, and the causative mutations identified and stratified by their ability to restore thrombus formation in larvae. Analysis of these novel mutations demonstrates variable residual FV function, with minimal activity being required to restore hemostasis in response to laser-induced endothelial injury. This in vivo evaluation may be beneficial for patients whose factor activity levels lack correlation with bleeding symptomatology, although limitations exist. Furthermore, homozygous mutant embryos tolerate what is a severe and lethal defect in mammals, suggesting the possibility of species-specific factors enabling survival, and allowing further study not possible in the mouse. Identification of these factors or other genetic modifiers could lead to novel therapeutic modalities.

UR - http://www.scopus.com/inward/record.url?scp=85067459563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067459563&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2018029066

DO - 10.1182/bloodadvances.2018029066

M3 - Article

VL - 3

SP - 1670

EP - 1680

JO - Blood advances

JF - Blood advances

SN - 2473-9529

IS - 11

ER -